Literature DB >> 12892797

Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications.

Philippe Morice1, Franklin Joulie, Sophie Camatte, David Atallah, Roman Rouzier, Patricia Pautier, Christophe Pomel, Catherine Lhommé, Pierre Duvillard, Damienne Castaigne.   

Abstract

BACKGROUND: The purpose was to determine the factors influencing nodal involvement and topography of pelvic and paraaortic node involvement in ovarian carcinoma. STUDY
DESIGN: Between 1985 and 2001, 276 women with epithelial ovarian carcinoma underwent systematic bilateral pelvic and paraaortic lymphadenectomy.
RESULTS: The overall frequency of lymph node involvement was 44% (122 of 276). The frequency of pelvic and paraaortic metastases were 30% (82 of 276) and 40% (122 of 276), respectively. The frequency of lymph node metastases according to the stage of the disease (stages I, II, and III + IV) were: 20% (17 of 85), 40% (6 of 15), and 55% (99 of 176), respectively. In patients with stage IA, IB, and IC disease, the rates of nodal involvement were 13% (8 of 60), 33% (4 of 12), and 38% (5 of 13), respectively. None of 15 patients with stage IA grade 1 disease had nodal involvement. None of the 20 patients with mucinous tumors confined to the ovary(ies) (stage I disease) had nodal involvement. When paraaortic nodes were involved, the left paraaortic chain above the level of the inferior mesenteric artery was the most frequently involved site (70 patients, 63%). One of nine patients (11%) with a macroscopic stage I unilateral tumor and paraaortic involvement had contralateral metastases.
CONCLUSIONS: Lymphadenectomy should be performed even in patients with stage IA disease. This procedure could be omitted in patients with mucinous apparent stage I disease and stage I grade 1 tumor. Lymphadenectomy should involve the whole pelvic and paraaortic chain up to the level of the left renal vein. A bilateral dissection should be performed even in cases of patients with a unilateral tumor.

Entities:  

Mesh:

Year:  2003        PMID: 12892797     DOI: 10.1016/S1072-7515(03)00234-5

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  38 in total

1.  Impact of Lymph Node Sampling in Stage II and III Epithelial Ovarian Cancer Patients with Clinically Negative Lymph Nodes.

Authors:  Mohamed Ibrahim Fahim; Abdelmaksoud Mohamed Ali; Rasha Mahmoud Allam
Journal:  Indian J Surg Oncol       Date:  2019-12-02

Review 2.  Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.

Authors:  Kimio Ushijima
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

3.  Differential routes of carboplatin administration influence lymphocyte apoptosis in retroperitoneal lymph nodes.

Authors:  Yong-Wen Huang; Zheng Zeng; Su Li; Ji-Hong Liu
Journal:  Tumour Biol       Date:  2012-07-29

Review 4.  Lymphadenectomy in Ovarian Cancer: Is It Still Justified?

Authors:  Pierluigi Benedetti Panici; Andrea Giannini; Margherita Fischetti; Francesca Lecce; Violante Di Donato
Journal:  Curr Oncol Rep       Date:  2020-02-08       Impact factor: 5.075

5.  Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.

Authors:  Shanshan Yang; Huiyan Li; Yunduo Liu; Xiaoming Ning; Fanling Meng; Min Xiao; Deying Wang; Ge Lou; Yunyan Zhang
Journal:  Med Oncol       Date:  2012-12-18       Impact factor: 3.064

6.  Clinical significance of para-aortic lymph node dissection and prognosis in ovarian cancer.

Authors:  Xianxian Li; Hui Xing; Lin Li; Yanli Huang; Min Zhou; Qiong Liu; Xiaomin Qin; Min He
Journal:  Front Med       Date:  2014-01-25       Impact factor: 4.592

Review 7.  Mucinous cystic neoplasms.

Authors:  Carlos Fernández-del Castillo
Journal:  J Gastrointest Surg       Date:  2007-10-23       Impact factor: 3.452

8.  Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients.

Authors:  Stefano Crippa; Roberto Salvia; Andrew L Warshaw; Ismael Domínguez; Claudio Bassi; Massimo Falconi; Sarah P Thayer; Giuseppe Zamboni; Gregory Y Lauwers; Mari Mino-Kenudson; Paola Capelli; Paolo Pederzoli; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2008-04       Impact factor: 12.969

Review 9.  [The role of radical lymphadenectomy. Experiences from the AGO Ovarian Cancer Study Group].

Authors:  P Wimberger; R Kimmig
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

10.  Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.

Authors:  Jennifer J Mueller; Marie Holzapfel; Chan H Han; Kevin Santos; Camille Gunderson; Kathleen Moore; Britt Erickson; Charles A Leath; Elena Diaz; Christine Walsh; Stephanie L Wethington; Sheila Z Dejbakhsh; Richard R Barakat; Ginger J Gardner; David M Hyman; Robert A Soslow; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.